1Wei M, Popescu N, Lernan M,et al. Localization of the human vascular endothelial growth factor gene, VEGF, at chromosome 6p21 [ J].Hum Genet, 1996,97:794 ～ 797.
2Kimitoshi M, Schmeck F, Gagnon M, et al. The value of vascular endothelial groth factor in human tumors [ J ]. Am J Path, 1995,14 ( 3 ):189 ～ 191.
3Suziki K, SASAki H, Kim S, et al. The vascular endothelial groth factor of human liver cancer and its metastasis[ J]. J Clin Incest, 1995,95:1789 ～ 1792.
4Brown L, Brase B, Jackman R, et al. Expression of vascular permeability factor ( vascular endothelial groth factor) and itsreceptor in breast cancer[J]. Am J Path,1995,146(2) :357 ～360.
5Warren R, Yuan H, Multi M, et al. Regulation by vascular endothelial growth factor of human colon cancer umorigenesis in a mouse model [J]. J Clin Invest, 1995,95:1789 ～ 1795.
6Melny K, schuman MA, kimk J. VEGF promotes tumor dissemination by a mechanism distinct from its effects on primary tumor growth[J].Cancer Res, 1996,56:921 ～ 928.
7Asano M, Ykita A, Matsumoto T, et al. Inhibition of tumor growth and metastasis by an immunoneutralizing monocional antibody to human vascular endothelial growth factor/vascular permeability factor 121[J]. J Cancer Res,1995,55(22) :5296 ～5301.
8Gordon M,Margolin K,Talpaz M,et al. Phase 1 safety and pharmacokinetic study of recombinant human anti-vascular growth factor in patients withadvanced cancer [ J ]. J Clin Oncol, 2001,19 ( 3 ): 843 ～850.
9Laird A,Vajkoczy P,Shawver L,et al. SU6688 is a potent anti-tumor agent that induces regression of established tumors[ J]. J Cancer Res,2000,60( 15 ) :4152 ～4160.
10Kaya M, Wada T,Akatsuka T,et al. Vascular endothelial growth factor expression in untreated osteosarcoma is predictive of pulmonary metastasis and poor prognosis [ J ]. Clin-Cancer-Res, 2000,6 ( 2 ): 572 ～577.
7WittigJC, Bickels J, Priebat D, et al. Osteosarcoma:a multidisciplinary approach to diagnosis and treatment [J]. Am Faro Physician, 2002, 65(6): 1123-1132
8Bacci G, Ferrari S, Longhi A, et al. Relationship between doseintensity of treatment and outcome for patients with osteosarcoma of the extremity treated with neoadjuvant chemotherapy[J]. Oncol Pep, 2001, 8(4): 883-888
9Fagioli F, Aglietta M, Tienghi A, et al. High-dose chemotherapy in the treatment of relapsed osteosarcoma :an Italian sarcoma group study[J]. Clin Oncol, 2002, 20(8): 2150
10Delepine N, Delepine G, Bacci G, et al. Influence of methotrexate dose intensity on outcome of patients with high grade osteogenic osteosarcoma. Analysis of the literature [J]. Cancer, 1996, 78(10):2127-2135
